- Home
- FBLG vs CMRX Comparison
FBLG vs CMRX Comparison
Compare FBLG & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBLG
- CMRX
- Stock Information
- Founded
- FBLG 2021
- CMRX 2000
- Country
- FBLG United States
- CMRX United States
- Employees
- FBLG N/A
- CMRX N/A
- Industry
- FBLG
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- FBLG
- CMRX Health Care
- Exchange
- FBLG NYSE
- CMRX Nasdaq
- Market Cap
- FBLG 91.0M
- CMRX 77.1M
- IPO Year
- FBLG 2024
- CMRX 2013
- Fundamental
- Price
- FBLG $2.41
- CMRX $0.91
- Analyst Decision
- FBLG Strong Buy
- CMRX Strong Buy
- Analyst Count
- FBLG 3
- CMRX 2
- Target Price
- FBLG $13.33
- CMRX $8.50
- AVG Volume (30 Days)
- FBLG 202.7K
- CMRX 298.2K
- Earning Date
- FBLG 11-12-2024
- CMRX 11-07-2024
- Dividend Yield
- FBLG N/A
- CMRX N/A
- EPS Growth
- FBLG N/A
- CMRX N/A
- EPS
- FBLG N/A
- CMRX N/A
- Revenue
- FBLG N/A
- CMRX $159,000.00
- Revenue This Year
- FBLG N/A
- CMRX $1,772.84
- Revenue Next Year
- FBLG N/A
- CMRX N/A
- P/E Ratio
- FBLG N/A
- CMRX N/A
- Revenue Growth
- FBLG N/A
- CMRX N/A
- 52 Week Low
- FBLG $1.08
- CMRX $0.75
- 52 Week High
- FBLG $46.00
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- FBLG 39.00
- CMRX 48.79
- Support Level
- FBLG $2.87
- CMRX $0.83
- Resistance Level
- FBLG $2.72
- CMRX $1.12
- Average True Range (ATR)
- FBLG 0.38
- CMRX 0.09
- MACD
- FBLG -0.12
- CMRX -0.01
- Stochastic Oscillator
- FBLG 14.94
- CMRX 28.86
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.